Latest Conference Articles

October 17th 2015, 8:15am

NANETS Symposium

Lu-Dotatate demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR in patients with progressive, metastatic midgut neuroendocrine tumors.

October 17th 2015, 8:12am

NANETS Symposium

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses results of the RADIANT-4 study, which examined the safety and efficacy of everolimus in advanced nonfunctional neuroendocrine tumors (NETs) of lung or gastrointestinal origin.

October 16th 2015, 3:39pm

NANETS Symposium

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

October 16th 2015, 3:17pm

NANETS Symposium

Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies.

October 16th 2015, 2:22pm

NANETS Symposium

Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.

October 16th 2015, 12:54pm

NANETS Symposium

The efficacy of several predictive markers previously thought to determine which patients might respond to temozolomide-based therapy could not be validated for patients with pancreatic neuroendocrine tumors.

October 16th 2015, 12:12pm

NANETS Symposium

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.

October 16th 2015, 11:53am

NANETS Symposium

Full surgical resection of gastroenteropancreatic neuroendocrine tumors is associated with a greater than 90% survival rate at five years.

October 16th 2015, 6:29am

NANETS Symposium

Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.

October 16th 2015, 5:30am

NANETS Symposium

David C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.

October 7th 2015, 12:02pm

European Cancer Congress

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.

October 6th 2015, 1:05pm

European Cancer Congress

Matteo Lambertini, MD, Department of Medical Oncology, U.O. Oncologia Medica A, Hospital San Martino, Genova, Italy, discusses the use of luteinizing hormone-releasing hormone agonists (LHRHa) during chemotherapy to preserve ovarian function and fertility in patients with breast cancer.

October 2nd 2015, 2:21pm

European Cancer Congress

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses treatment challenges for patients with refractory, metastatic urothelial carcinoma.

October 1st 2015, 8:52am

European Cancer Congress

Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non–small cell lung cancer (NSCLC).

September 30th 2015, 2:47pm

European Cancer Congress

Catherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses novel targeted therapy rovalpituzumab tesirine (Rova-T), which showed activity in relapsed and refractory small cell lung cancer (SCLC) in a recent phase I study.

September 30th 2015, 7:04am

European Cancer Congress

Treatment with telotristat etiprate reduced the average number of daily bowel movements by up to 35% for patients with carcinoid syndrome that was not adequately controlled by a somatostatin analog.

September 29th 2015, 8:39am

European Cancer Congress

Treatment with the frontline combination of erlotinib and bevacizumab was highly effective in patients with advanced non–small cell lung cancer who harbored an EGFR T790M mutation.

September 28th 2015, 4:15pm

European Cancer Congress

Treatment with nivolumab reduced the risk of death by 28% compared with docetaxel for patients with previously treated nonsquamous non–small cell lung cancer.

September 28th 2015, 3:13pm

European Cancer Congress

The antibody-drug conjugate rovalpituzumab tesirine demonstrated activity across a range of patients with relapsed and refractory small-cell lung cancer.

September 28th 2015, 11:38am

European Cancer Congress

Data from the pivotal KEYNOTE-001 trial showing pembrolizumab's efficacy in pretreated non–small cell lung cancer (NSCLC) were presented at the 2015 European Cancer Congress, just days before the FDA is scheduled to make its approval decision on the PD-1 inhibitor in this setting.